Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3461-3467

  Chen, Guoan ^a   Wang, Xiaoju ^a   Yu, Jianjun ^a   Varambally, Sooryanarayana ^a   Yu, Jindan ^a   Thomas, Dafydd G ^a   Lin, Mu Yen ^a   Vishnu, Prakash ^a   Wang, Zhuwen ^a   Wang, Rui ^a   Fielhauer, Jeff ^a   Ghosh, Debashis ^a   Giordano, Thomas J ^a   Giacherio, Donald ^a   Chang, Andrew C ^a   Orringer, Mark B ^a   El Hefnawy, Talal ^b   Bigbee, William L ^b   Beer, David G ^a   Chinnaiyan, Arul M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; MESSENGER RNA; PROTEIN UBIQUILIN 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CANCER ANTIBODY; CARRIER PROTEIN; CELL CYCLE PROTEIN; PEPTIDE LIBRARY; UBQLN1 PROTEIN, HUMAN;

ARTICLE; BACTERIOPHAGE T7; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; LUNG ADENOCARCINOMA; LUNG TUMOR; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; ADENOCARCINOMA; ANTIBODY PRODUCTION; BIOSYNTHESIS; BLOOD; GENETICS; IMMUNOLOGY;

ADENOCARCINOMA; ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; AUTOANTIBODIES; BACTERIOPHAGE T7; CARRIER PROTEINS; CELL CYCLE PROTEINS; HUMANS; LUNG NEOPLASMS; PEPTIDE LIBRARY; PROTEIN ARRAY ANALYSIS; RNA, MESSENGER;

EID: 34248224081     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4475     Document Type: Article

References (50)

1. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
2. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999;86:1867-76.
3. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5.
4. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001;98:13784-9.
5. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
6. Balsara BR, Sonoda G, du Manoir S, Siegfried JM, Gabrielson E, Testa JR. Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human nonsmall cell lung carcinomas. Cancer Res 1997;57:2116-20.
7. Chen G, Gharib TG, Huang CC, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002;8:2298-305.
8. Chen G, Gharib TG, Wang H, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 2003;100:13537-42.
9. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003;362:433-9.
10. Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell 2004;6:433-8.
11. Chanin TD, Merrick DT, Franklin WA, Hirsch FR. Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present. Curr Opin Pulm Med 2004;10:242-7.
12. Bunn PJ, Jr. Early detection of lung cancer using serum RNA or DNA markers: ready for "prime time" or for validation? J Clin Oncol 2003;21:3891-3.
13. Krebs P, Kurrer M, Sahin U, Tureci O, Ludewig B. Autoimmunity seen through the SEREX-scope. Autoimmun Rev 2003;2:339-45.
14. Lee SY, Obata Y, Yoshida M, et al. Immunomic analysis of human sarcoma. Proc Natl Acad Sci U S A 2003;100:2651-6.
15. Xiao X, Liu D, Tang Y, et al. Development of proteomic patterns for detecting lung cancer. Dis Markers 2003;19:33-9.
16. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
17. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003;21:57-63.
18. Minenkova O, Pucci A, Pavoni E, et al. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int J Cancer 2003;106:534-44.
19. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998;187:1163-7.
20. Nilsson BO, Carlsson L, Larsson A, Ronquist G. Autoantibodies to prostasomes as new markers for prostate cancer. Ups J Med Sci 2001;106:43-9.
21. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001;98:9824-9.
22. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88.
23. Sreekumar A, Laxman B, Rhodes DR, et al. Humoral immune response to α-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 2004;96:834-43.
24. Mantovani A. Cancer: inflammation by remote control. Nature 2005;435:752-3.
25. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-23.
26. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
27. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res 2003;5:57-8.
28. Fathman CG, Soares L, Chan SM, Utz PJ. An array of possibilities for the study of autoimmunity. Nature 2005;435:605-11.
29. Fernandez-Madrid F, Tang N, Alansari H, et al. Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer. Cancer Res 2004;64:5089-96.
30. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35.
31. Zhong L, Hidalgo GE, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med 2005;172:1308-14.
32. Dybwad A, Bogen B, Natvig JB, Forre O, Sioud M. Peptide phage libraries can be an efficient tool for identifying antibody ligands for polyclonal antisera. Clin Exp Immunol 1995;102:438-42.
33. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.
34. Kim KY, Kim BJ, Yi GS. Reuse of imputed data in microarray analysis increases imputation efficiency. BMC Bioinformatics 2004;5:160.
35. Bo T, Jonassen I. New feature subset selection procedures for classification of expression profiles. Genome Biol 2002;3:RESEARCH0017.
36. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 2004;101:9309-14.
37. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
38. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002;1:304-13.
39. Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol 2002;9:505-11.
40. Tukey JW. Tightening the clinical trial. Control Clin Trials 1993;14:266-85.
41. Kleijnen MF, Shih AH, Zhou P, et al. The hPLIC proteins may provide a link between the ubiquitination machinery and the proteasome. Mol Cell 2000;6:409-19.
42. Mah AL, Perry G, Smith MA, Monteiro MJ. Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation. J Cell Biol 2000;151:847-62.
43. Hiltunen M, Lu A, Thomas AV, et al. Ubiquilin 1 modulates amyloid precursor protein trafficking and aβ secretion. J Biol Chem 2006;281:32240-53.
44. Thomas AV, Herl L, Spoelgen R, et al. Interaction between presenilin 1 and ubiquilin 1 as detected by fluorescence lifetime imaging microscopy and a high-throughput fluorescent plate reader. J Biol Chem 2006;281:26400-7.
45. Slifer MA, Martin ER, Haines JL, Pericak-Vance MA. The ubiquilin 1 gene and Alzheimer's disease. N Engl J Med 2005;352:2752-3; author reply -3.
46. Zhong L, Peng X, Hidalgo GE, Doherty DE, Stromberg AJ, Hirschowitz EA. Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect Prev 2003;27:285-90.
47. Zhong L, Peng X, Hidalgo GE, Doherty DE, Stromberg AJ, Hirschowitz EA. Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics 2004;4:1216-25.
48. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120-6.
49. Rossi S, Loda M. The role of the ubiquitination-proteasome pathway in breast cancer: use of mouse models for analyzing ubiquitination processes. Breast Cancer Res 2003;5:16-22.
50. Huebener N, Lode HN. AACR Special Conference in cancer research: ubiquitination in normal and cancer cells. Expert Opin Biol Ther 2003;3:187-92.